Novagali Pharma Presents Results of its Innovative Latanoprost Formulation fo... ( EVRY France February 27 /- Novaga...)

Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma

Date:2/27/2009

EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free latanoprost formulation for glaucoma.

Novagali communicated about "Ocular safety comparison of a latanoprost cationic emulsion versus conventional formulations of prostaglandin analogues: an in vivo toxicity assay" at the 9th Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) held in Salzburg, Austria. The experimental work has been performed in collaboration with Professor Christophe Baudouin from the Quinze-Vingts National Ophthalmology Hospital and Science Faculty of Paris V, France. Acute toxicological studies confirmed the ocular surface toxicity of anti-glaucomatous eye drops containing benzalkonimum chloride (BAK) while Novagali's BAK-free cationic emulsion of latanoprost was well tolerated and did not induce any ocular surface damages upon stress conditions.

Nova21027 is a topical ocular BAK-free emulsion of latanoprost relying on Novasorb(R) patented cationic emulsions technology. The company achieved a product that present a safer profile than BAK-containing marketed products for glaucoma. This feature is of paramount importance taken into account that BAK exerts toxicity after long term use and that glaucoma is a chronic disease needing life-long daily treatment.

"It is now admitted that BAK has a deleterious effect especially in ocular surface diseases and after long-term or combination therapies. This state-of-the art BAK-free formulation of latanoprost demonstrated both efficacy and safety in various preclinical models" says Jerome Martinez, CEO of Novagali.

"Our innovative formulation is also stable at room temperature, which makes our product more convenient from production to patients," explains Jean-Sebastien Garrigue, director o
'/>"/>

SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)

Post Your Comments:

(Date:12/2/2009).../ -- Reportlinker.com announces that a new market ..., Cardiac Pacemakers - A World Market Analysis ...iac-Pacemakers---A-World-Market-Analysis.html ,... a rapidly expanding cardiovascular devices market...cterized by relatively mature conditions and inten...

(Date:12/2/2009)...swire-FirstCall/ -- Varian, Inc. (Nasdaq: VARI ) ...filed with the U.S. Securities and Exchange Commis... year ended October 2, 2009. This Annual Report m...ww.varianinc.com, by clicking on "Investors" and "...n. Stockholders may receive a hard copy of this A...

(Date:12/2/2009).../ -- Reportlinker.com announces that a new market ..., Hemoglobin A1c Monitoring - Global Market Tren...moglobin-A1c-Monitoring---Global-Market-Trends.htm...d for effective therapy to manage diabetes has led...toring the treatment efficiency of the disease. Ot...

[0] Reportlinker Adds Cardiac Pacemakers - A World Market Analysis [0] Varian, Inc. Announces Form 10-K Filing [0] Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends

...if., June 3 Anesiva,Inc. (Nasdaq: ANSV ) today a...stration has approved Anesiva,s investigational ne...ng-acting, site specific, non-opioid drug,candidat...nt of acute pain,following orthopedic surgery. Ane... Adlea in patients undergoing arthroscopic shoulde...

...at Lymphoma Meeting in Lugano, Switzerland, SOUTH...ed an abstract providing preliminary results of a ...R788 (fostamatinib disodium), in,patients with rel... (NHL).,The abstract reports favorable responses f...oma/chronic lymphocytic leukemia (SLL/CLL) or from...

Other Medicine Technology:Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 2 Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 3 Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application 4 Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL 2 Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL 3 Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL 4

Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

(Date:12/2/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Renal Disease Treatments: Products and T...824/Renal-Disease-Treatments-Products-and-Therapie...ducts and services, providing data for 2008 and es...nd compound annual growth rates (CAGRs) from 2009 ...

(Date:12/2/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Antibiotic Resistance and Antibiotic Tec...tlinker.com/p0166825/Antibiotic-Resistance-and-Ant...ovide an in-depth review of the global market for ...s ,, Offer an analysis of antibiotics resistanc...

(Date:12/2/2009)...es, study finds , , WEDNESDAY, Dec. 2 (H...l rates for advanced lung cancer patients in the U...as found. , Researchers analyzed data on more t...all cell lung cancer (NSCLC) between 1990 and 2005... Cancer Institute,s Surveillance, Epidemiology and...

(Date:12/2/2009)...lic syndrome, study finds , , WEDNESDAY,...nough to keep overweight college football players ...that can lead to heart disease, a new study sugges... colleges and found that two-thirds were obese. Of... of conditions that raise the risk for heart disea...

(Date:12/2/2009)... By now, most people have heard of...nue to grow in popularity. And, the latest product...arette - the new single piece PremiumOne(TM) dispo...price of $14.99. ,, "This new product makes it ...ry low price, before making a bigger investment in...

[1] Reportlinker Adds Renal Disease Treatments: Products and Therapies [0] Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets [0] Gains Made in Lung Cancer Survival [0] Oversized College Football Players May Face Heart Risks [2] A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product

...- Traditionally, cancer biologists have embraced a...he tumor -- the "seed" -- was seen as bearing tota...nt tissues -- the "soil" in which the seed embedde...mor seed but neglecting the role of the soil. , R...

...ple who are blind or visually impaired are women ...e NGOs held a briefing, " Seeing Women: Taking on..." at the National Press Club in Washington, DC e... and effective strategies that work in improving a...

...rop in Mexico Hotel Search but 30% Increase in Car... , Site Poll Says Nearly One in Four Consider Saf... TripAdvisor(R), the world,s most popular and lar...ent swine flu scare. , , To view the Multimedia N...

...iversity] Statewide weight loss competitions appe...ttle against obesity. These programs can produce w...ost, according to a new study from The Miriam Hosp...leagues came to their conclusions after evaluating...

...as fat-burners, energy boosters, agency says , ...th officials are warning consumers to stay away fr... under the Iovate and MuscleTech brand names becau...fat burners and energy-boosters, is voluntarily re...

...idebook First to Compile International Laws, Rules...indicate, the need to keep a close eye on pharmace... to market the drug. , , In March 2008, shipment...eparin caused dozens of deaths and hundreds of inj...

Other Medicine News:Health News:Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche 2 Health News:NGOs Unite to Bring Awareness to Inequities in Eye Care for Women 2 Health News:Photos: Traveler Interest Shifts From Mexico to the Caribbean in Light of Swine Flu 2 Health News:Photos: Traveler Interest Shifts From Mexico to the Caribbean in Light of Swine Flu 3 Health News:Weight loss competitions produce encouraging results 2 Health News:FDA Recalls Dietary Supplements Tied to 1 Death, Liver Damage 2 Health News:New FDLI Book Maps Out Pharmacovigilance Provisions in More Than a Dozen Countries 2

Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche NGOs Unite to Bring Awareness to Inequities in Eye Care for Women Photos: Traveler Interest Shifts From Mexico to the Caribbean in Light of Swine Flu Weight loss competitions produce encouraging results FDA Recalls Dietary Supplements Tied to 1 Death, Liver Damage New FDLI Book Maps Out Pharmacovigilance Provisions in More Than a Dozen Countries

Seattle Small Joint Arthroscopy Curved Osteotome

ECTRA II System 25 mm

Teardrop punch, Left

Meniscus Screw

Medicine Products:

Seattle Small Joint Arthroscopy Curved Osteotome ECTRA II System 25 mm Teardrop punch, Left Meniscus Screw

Novagali Pharma Presents Results of its Innovative Latanoprost Formulation fo...( EVRY France February 27 /- Novaga...),Health